C12Q 2600/136
Screening for pharmacological compounds
C12Q2600/136 (Screening for pharmacological compounds) appears on 2,434 US grants and 5,710 published applications in this corpus.
Search patents in C12Q- Granted patents
- 2,434
- Published applications
- 5,710
- Assignees
- 1,642
- Inventors
- 7,882
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 2 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 3 | 0 |
| 1994 | 2 | 0 |
| 1995 | 4 | 0 |
| 1996 | 8 | 0 |
| 1997 | 24 | 0 |
| 1998 | 33 | 0 |
| 1999 | 36 | 0 |
| 2000 | 30 | 0 |
| 2001 | 52 | 12 |
| 2002 | 48 | 126 |
| 2003 | 44 | 1093 |
| 2004 | 42 | 240 |
| 2005 | 31 | 257 |
| 2006 | 62 | 282 |
| 2007 | 154 | 270 |
| 2008 | 166 | 194 |
| 2009 | 99 | 306 |
| 2010 | 145 | 324 |
| 2011 | 134 | 365 |
| 2012 | 121 | 271 |
| 2013 | 116 | 236 |
| 2014 | 107 | 182 |
| 2015 | 124 | 244 |
| 2016 | 103 | 262 |
| 2017 | 120 | 196 |
| 2018 | 120 | 175 |
| 2019 | 115 | 140 |
| 2020 | 111 | 113 |
| 2021 | 87 | 98 |
| 2022 | 56 | 80 |
| 2023 | 49 | 80 |
| 2024 | 36 | 66 |
| 2025 | 38 | 57 |
| 2026 | 12 | 41 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method for predicting and evaluating antimicrobial therapy when molecular PCR diagnostic testing results yield multi-organisms and multi-resistant bacteria from a single DNA sample22 Sep 2026US 12,742,212 B2Advanced Therapeutic Assist
- FUS/TLS-based compounds and methods for diagnosis, treatment and prevention of amyotrophic lateral sclerosis and related motor neuron diseases15 Sep 2026US 12,735,745 B2The General Hospital Corporation
- Methods and composition for modulating immune response and immune homeostasis11 Aug 2026US 12,702,696 B2Massachusetts Institute of Technology
- Spatiotemporally resolved transcriptomics at subcellular resolution16 Jun 2026US 12,655,474 B2Massachusetts Institute of Technology
- Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments19 May 2026US 12,630,890 B2Regeneron Pharmaceuticals, Inc.
- Replicon dna, cloning vector, screening kit, screening method, anti-nobecov-irus agent, beta-coronavirus proliferation inhibitor, pan beta-coronavirus inhibitor, virus proliferation inhibitor, hepatitis c virus proliferation inhibitor, and method for screening therapeutic agent for viral infectious disease8 Oct 2026US 2026/0308206 A1Kagoshima University
- Wrinkle determination of a human individual1 Oct 2026US 2026/0297652 A1Beiersdorf AG
- Assays for monitoring inhibition of rna helicase dhx91 Oct 2026US 2026/0297679 A1Accent Therapeutics, Inc.
- Abi1 regulates transcriptional activity of androgen receptor by novel dna and ar binding mechanism1 Oct 2026US 2026/0297683 A1The Johns Hopkins University
- Screening for host-microbe interactions24 Sep 2026US 2026/0286447 A1Kanvas Biosciences, Inc.
Most cited
By later US patents
- Methods of assigning treatment to breast cancer patients186US 7,171,311 B2Rosetta Inpharmatics LLC · 2007
- Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments172US 7,294,468 B2Dana-Farber Cancer Institute, Inc. · 2007
- MicroRNA molecules169US 7,232,806 B2MAX-PLANCK-GESELLSCHAFT zur FOERDERUNG der WISSENSCHAFTEN.e.V · 2007
- Therapy and diagnosis of conditions related to telomere length and/or telomerase activity143US 5,489,508 AUniversity of Texas System Board of Regents · 1996
- Apparatus and method for drug screening137US 6,849,403 B1Exact Sciences Corporation · 2005